Mammoth Biosciences has received US FDA emergency use authorization (EUA) for its DETECTR BOOST SARS-CoV-2 Reagent Kit, a high-throughput solution. The platform is a turnkey, CRISPR-based molecular diagnostic system that enables high-throughput, sample-to-answer testing with PCR-equivalent performance and minimal hands-on time. Together with the Agilent Bravo BenchCel DB liquid handling platform, the kit is designed to detect SARS-CoV-2 RNA in nasopharyngeal, anterior nasal, mid-turbinate nasal or oropharyngeal swab specimens from individuals suspected of COVID-19 by their health care provider, and the test is performed in high complexity CLIA laboratories.

• Mammoth Biosciences, Inc
  For more information, see the reader service card.